# US 2004/0081971 A1 · Protein modification and maintenance molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081971 A1
- Document ID: US20040081971A1
- Status: Published application
- Kind: A1
- Application number: 10/312,315
- Filed: 2002-12-19
- Published: 2004-04-29
- Earliest claimed: 2000-06-30
- Inventors: Henry Yue; Preeti G Lal; Narinder K Chawla; Y Tom Tang; Dyung Aina M Lu; Monique G Yao; Danniel B Nguyen; April J A Hafalia; Chandra S Arvizu; Angelo M Delegeane; Yan Lu; Nei Burford; Jennifer L Policky; Ameena R Gandhi; Jayalaxmi Ramkumar; Farrah A Khan; Kavitha Thangavelu; Yuming Xu; Kimberly J Gietzen
- Web page: https://patentgrep.com/patent/US20040081971A1

## CPC

- C07K 14/47: from mammals
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/24: of the sex hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/12: for cataracts
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/10: Anthelmintics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides human protein modification and maintenance molecules (PMMM) and polynucleotides which identify and encode PMMM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PMM.

## Claims

### Claim 1

An isolated polypeptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8,
b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8,
c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and
d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 2 (depends on 1)

An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-8.

### Claim 3 (depends on 1)

An isolated polynucleotide encoding a polypeptide of claim 1.

### Claim 4 (depends on 2)

An isolated polynucleotide encoding a polypeptide of claim 2.

### Claim 5 (depends on 4)

An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:9-16.

### Claim 6 (depends on 3)

A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

### Claim 7 (depends on 6)

A cell transformed with a recombinant polynucleotide of claim 6.

### Claim 8 (depends on 6)

A transgenic organism comprising a recombinant polynucleotide of claim 6.

### Claim 9 (depends on 1)

A method for producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
b) recovering the polypeptide so expressed.

### Claim 10 (depends on 1)

An isolated antibody which specifically binds to a polypeptide of claim 1.

### Claim 11

An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16,
b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16,
c) a polynucleotide complementary to a polynucleotide of a),
d) a polynucleotide complementary to a polynucleotide of b), and
e) an RNA equivalent of a)-d).

### Claim 12 (depends on 11)

An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

### Claim 13 (depends on 11)

A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

### Claim 14 (depends on 13)

A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

### Claim 15 (depends on 11)

A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

### Claim 16 (depends on 1)

A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 16)

A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 18 (depends on 16)

A method for treating a disease or condition associated with decreased expression of functional PMMM, comprising administering to a patient in need of such treatment the composition of claim 16.

### Claim 19 (depends on 1)

A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

### Claim 20 (depends on 19)

A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

### Claim 21 (depends on 20)

A method for treating a disease or condition associated with decreased expression of functional PMMM, comprising administering to a patient in need of such treatment a composition of claim 20.

### Claim 22 (depends on 1)

A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.

### Claim 23 (depends on 22)

A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

### Claim 24 (depends on 23)

A method for treating a disease or condition associated with overexpression of functional PMMM, comprising administering to a patient in need of such treatment a composition of claim 23.

### Claim 25 (depends on 1)

A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

### Claim 26 (depends on 1)

A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

### Claim 27 (depends on 5)

A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
b) detecting altered expression of the target polynucleotide, and
c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

### Claim 28 (depends on 11)

A method for assessing toxicity of a test compound, said method comprising:
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and
d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

### Claim 29 (depends on 10)

A diagnostic test for a condition or disease associated with the expression of PMMM in a biological sample comprising the steps of:
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody polypeptide complex; and
b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

### Claim 30 (depends on 10)

The antibody of claim 10, wherein the antibody is:
a) a chimeric antibody,
b) a single chain antibody,
c) a. Fab fragment,
d) a F(ab′)2 fragment, or
e) a humanized antibody.

### Claim 31 (depends on 10)

A composition comprising an antibody of claim 10 and an acceptable excipient.

### Claim 32 (depends on 31)

A method of diagnosing a condition or disease associated with the expression of PMMM in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

### Claim 33 (depends on 31)

A composition of claim 31, wherein the antibody is labeled.

### Claim 34 (depends on 33)

A method of diagnosing a condition or disease associated with the expression of PMMM in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

### Claim 35 (depends on 10)

A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and
c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 36 (depends on 35)

An antibody produced by a method of claim 35.

### Claim 37 (depends on 36)

A composition comprising the antibody of claim 36 and a suitable carrier.

### Claim 38 (depends on 10)

A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and
e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 39 (depends on 38)

A monoclonal antibody produced by a method of claim 38.

### Claim 40 (depends on 39)

A composition comprising the antibody of claim 39 and a suitable carrier.

### Claim 41 (depends on 10)

The antibody of claim 10, wherein the antibody is produced by screening a. Fab expression library.

### Claim 42 (depends on 10)

The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

### Claim 43 (depends on 10)

A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 in a sample, comprising the steps of:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 in the sample.

### Claim 44 (depends on 10)

A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 from a sample, the method comprising:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 45 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

### Claim 46 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

### Claim 47 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

### Claim 48 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

### Claim 49 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

### Claim 50 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

### Claim 51 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

### Claim 52 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

### Claim 53 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:9.

### Claim 54 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:10.

### Claim 55 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:11.

### Claim 56 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:12.

### Claim 57 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:13.

### Claim 58 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:14.

### Claim 59 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:15.

### Claim 60 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:16.

### Claim 61 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:1.

### Claim 62 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:2.

### Claim 63 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:3.

### Claim 64 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:4.

### Claim 65 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:5.

### Claim 66 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:6.

### Claim 67 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:7.

### Claim 68 (depends on 9)

A method of claim 9, wherein the polypeptide has the sequence of SEQ ID NO:8.

### Claim 69 (depends on 12)

A microarray wherein at least one element of the microarray is a polynucleotide of claim 12.

### Claim 70 (depends on 69)

A method for generating a transcript image of a sample which contains polynucleotides, the method comprising the steps of:
a) labeling the polynucleotides of the sample,
b) contacting the elements of the microarray of claim 69 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
c) quantifying the expression of the polynucleotides in the sample.

### Claim 71 (depends on 11)

An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, said target polynucleotide having a sequence of claim 11.

### Claim 72 (depends on 71)

An array of claim 71, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

### Claim 73 (depends on 71)

An array of claim 71, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

### Claim 74 (depends on 71)

An array of claim 71, which is a microarray.

### Claim 75 (depends on 71)

An array of claim 71, further comprising said target polynucleotide hybridized to said first oligonucleotide or polynucleotide.

### Claim 76 (depends on 71)

An array of claim 71, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

### Claim 77 (depends on 71)

An array of claim 71, wherein each distinct physical location on the substrate contains multiple nucleotide molecules having the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another physical location on the substrate.
